Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	37.37B -18.6%
Revenue (ttm)	7.35B -10.1%
Net Income	1.58B -28.1%
EPS	0.24 -27.3%
Shares Out	6.56B
PE Ratio	23.75
Forward PE	20.36
Dividend	0.05 (0.85%)
Ex-Dividend Date	Feb 10, 2026

Volume	22,592,870
Average Volume	28,247,534
Open	5.72
Previous Close	5.74
Day's Range	5.67 - 5.73
52-Week Range	5.61 - 7.26
Beta	0.44
RSI	36.74
Earnings Date	Mar 27, 2026

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 4,045
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2025, SHE:002252's revenue was 7.35 billion, a decrease of -10.13% compared to the previous year's 8.18 billion. Earnings were 1.58 billion, a decrease of -28.10%.